In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme's Manufacturing Problems

Executive Summary

Genzyme looks increasingly vulnerable after the temporary closure of its Allston manufacturing facility resulted in shortages of one of its primary products, Cerezyme. Analysts remain divided on the long-term consequences, but there's no denying the the gaffes have created an opening for medicines from competitors Shire and Protalix.
Advertisement

Related Content

Sanofi Pursues Genzyme, But For How Long?
Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
Genzyme, J&J Manufacturing Troubles Highlight The Importance Of Quality Systems
Genzyme, J&J Manufacturing Troubles Highlight The Importance Of Quality Systems
For Shire, Life After Adderall XR? Yes
For Shire, Life After Adderall XR? Yes
Genzyme: Why Diversification is Starting to Look Smart
Genzyme: Why Diversification is Starting to Look Smart
Novartis's Research Experiment
Novartis's Research Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel